Navigation Links
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Date:5/12/2008

ANN ARBOR, Mich., May 12 /PRNewswire/ -- Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this drug may be an important therapy for RA patients.

"The successful completion of the first studies in healthy human volunteers is an important milestone in developing VEL-0230 as a therapy," said Michael W. Long, PhD, President and Chief Executive Officer of Velcura. "While we are still analyzing and tabulating the data, our preliminary conclusions are that the drug is safe and well-tolerated over a range of doses."

"During this initial safety study in humans, the drug caused a rapid (within 15 minutes) and marked (80%) reduction in CTx levels, a biomarker of bone resorption. Our next step is to evaluate the drug for efficacy in RA patients," said Dr. Long who added, "We plan to move into multiple clinical studies as rapidly as possible."

VEL-0230 is being studied as an orally available molecule that promotes bone formation, inhibits bone loss and reduces inflammation. If successful in RA patients Velcura Therapeutics plans to study it as a treatment for other bone disorders, such as bone loss related to multiple myeloma, bone metastases, and osteoporosis.

About Velcura Therapeutics, Inc.

Velcura Therapeutics, Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, therapies that restore the balance between bone building an
'/>"/>

SOURCE Velcura Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
2. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
9. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...7 At the upcoming Radiological Soc...ng Sunday, Royal Philips Electronics ( PHG, AEX: P...ging and informatics solutions designed to directl...iders, by delivering meaningful imaging innovation...oints and easy upgradability. This focus will ena...
(Date:11/25/2009)... Nov. 25 Heska Corporati...anced diagnostic and specialty products to the vet...Roche Diagnostics Corporation for the supply of bl...e veterinary market. ,, (Logo: http://www...., "Heska and Roche share the same passion for inno...
(Date:11/25/2009)...Switzerland, Nov. 25 From Novembe...ative hearing solutions, presented the second edit...using on the special needs of the older population...in aging and audiology from around the world and m...er people with hearing loss for an opportunity to ...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3The Donor Source International LLC Opens Office in New England 55076 1Dominique Wilkins Scores Big for Diabetes in Fayette County 55073 1Dominique Wilkins Scores Big for Diabetes in Fayette County 55073 2Dominique Wilkins Scores Big for Diabetes in Fayette County 55073 3Dopamine Lets Bad Experiences Linger 55071 1Dopamine Lets Bad Experiences Linger 55071 2Dopamine Lets Bad Experiences Linger 55071 3
...l, a leading,global provider of information resour...day announced the addition of a robust new drug,ef...pharmacy education,resource, AccessPharmacy (http...ith,Doctor Evidence, developer of distributed data...acy now provides in-context access to drug efficac...
...n and is Well Tolerated in Hunt...Further Development in Huntington,s Disease - ....m. EDT -, SAN FRANCISCO, July 7 Medivation, Inc...s of a Phase 2 study showing,that its investigatio...ive,function in patients with mild-to-moderate Hun...
Other Medicine Technology:McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy 2Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease 2Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease 3Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease 4Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease 5
(Date:11/29/2009)... Traditional healthcare,s uncertai... affordable alternative care. Affordable Acupunctu... (PRWEB) November 29, 2009 -- Affordable A...is year (2009) and has been met with enthusiasm an...uccess can be attributed to two things, need and c...
(Date:11/28/2009)..., CHICAGO, Nov. 28 Get ready f...ice in the clinical routine when Siemens intro...Assembly and Annual Meeting of the Radiological So...December 3 at McCormick Place (Booth #825, East Bu... syngo. via , Siemens, new imaging software ...
(Date:11/28/2009)...ds gene variation believed to affect circadian rhy... News) -- New research suggests that an internal b... in the development of bipolar disorder in childre...of the genetic makeup of 152 children with bipolar...jor mood swings, and 140 children without the diso...
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today...1 virus genomic data. It shows that the lethality...d. 4.5) during the virus,s current outbreak in the...s week of 2.0 (s.d. 0.1). The H1N1 infectivity cou... Boston (PRWEB) November 27, 2009 -- Biote...
Breaking Medicine News(10 mins):Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5
...neurological symptoms have higher chance of proble...(HealthDay News) -- Newborns who were not breathin...eased risk of having a low IQ, even if they showed...ebral palsy is a period of lack of oxygen, newborn...
...l 20 Boston Scientific Corporation (NYSE: BSX )...uarter ended March 31, 2009, as well as guidance f...second quarter and full year of 2009. , , , Fi...h in line with guidance (GAAP loss per share of $0...
... 20 The managing director of Publication CONNEXIO...d to speak at the 45th Annual Drug Information Ass.... Singer will be present a talk entitled "Effectiv...s from all facets within the industry. , , Follo...
... the only reason lizards and other cold-blooded cr...shed in the May/June issue of Physiological and B...hing behavior based on their need for vitamin D. ,... University who led the study. "Our results sugges...
... Young Innovations, Inc. (Nasdaq: YDNT ) today ... earnings results with a live and on-demand web ca...1:00 a.m. Central Time. A live audio broadcast of...ugh the Company,s website, www.ydnt.com . , , ...
...il 20 Insulet Corporation (Nasdaq: PODD ), the ... its OmniPod(R) Insulin Management System, announc...first quarter 2009 on Thursday, May 7, 2009 after ...rst quarter 2009 financial results. During the con...
Other Medicine News:Health News:Resuscitated Newborns at Risk for Lower IQs 2Health News:Resuscitated Newborns at Risk for Lower IQs 3Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 2Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 3Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 4Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 5Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 6Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 7Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 8Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 9Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 10Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 11Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 12Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 13Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 14Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 15Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 16Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 17Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 18Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 19Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 20Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 21Health News:Study: Lizards bask for more than warmth 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Insulet Corporation to Report First Quarter 2009 Financial Results on Thursday, May 7, 2009 2
Freedom Clear® LS External Catheters
Natural Male External Catheters
...Medical® clear, all-silicone Foley catheters e...oley catheter designs. As an inert, toxin-free ela...endable Foley catheter. Unlike silicone-coated lat...ers will not leach chemicals or water-soluble prot...
...lled-release nitrofurazone Foley catheter, RELEASE...eter is the first and only Foley that works as a d... RELEASE-NF catheter delivers the drug nitrofurazo... of the urethral tract. Unlike coated catheters, w...
Medicine Products: